Certican derives Successful Result

.

Certican derives Successful Result

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

In addition, it has been said that the project is considered to be the biggest project that has been taken out by the company with regard to liver transplant. It has been found that the drug is quite effective in improving renal function among patients.

The data about the same was revealed at the meeting of American Association for the Study of Liver Diseases (AASLD), which is in its 63rd year. The drug, which has already received approval from European health authorities, is likely to get approval from the US health regulators Food and Drug Administration by the end of 2012.

"These results showed that treatment with Certican with reduced tacrolimus led to a clinically relevant retention of renal function compared to standard tacrolimus, with no compromise in rejection", said John Fung, who is positioned as director at Transplantation Center. It is expected that the drug is able to provide benefit to adults suffering from liver problem.


Latest News

Hawaii Tourism Authority Optimistic yet Cautious About Growth in Tourism for 201
New App on Instagram Allows You to Buy What You Like Instantly
The Economy of Japan Shows Signs Of Weakness and Stagnation
Abercrombie Planning to Trim Down the Logo
South Korean Automaker Kia to Construct a $1 Billion Car Assembly Plant In Mexic
Deal Reached Finally for Market Basket: Ex CEO to Buy the Supermarket Chain
Latest Funding Value Snapchat at $10 billion
American Airlines Pulls Listing and Fares from Orbitz Due to Unsuccessful Effort
Is Burger King’s Deal with Tim Hortons Going to Affect Its Popularity?
Fans Show Twitch’s $970 Million Acquisition is Worth It
Ann Taylor (ANN) Shares Increase as Activist and Investors Put Pressure for Sale
Though The Market Basket Employees are Disappointed But They are not Giving up P